TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

28 Jul 2025 08:52:49 By Nasdaq GlobeNewswire

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

18 Jul 2025 09:36:44 By Nasdaq GlobeNewswire

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

17 Jul 2025 06:15:00 By Nasdaq GlobeNewswire

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

16 Jul 2025 08:57:19 By Nasdaq GlobeNewswire

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

14 Jul 2025 06:30:00 By Nasdaq GlobeNewswire

Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

10 Jul 2025 12:13:07 By Nasdaq GlobeNewswire

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

30 Jun 2025 11:28:47 By Nasdaq GlobeNewswire

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

18 Jun 2025 05:30:00 By Nasdaq GlobeNewswire

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

09 Jun 2025 06:00:00 By Nasdaq GlobeNewswire

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

30 May 2025 08:01:18 By Nasdaq GlobeNewswire

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

23 May 2025 12:49:51 By Nasdaq GlobeNewswire

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

22 May 2025 10:21:42 By Nasdaq GlobeNewswire

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

12 May 2025 05:00:00 By Nasdaq GlobeNewswire

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

02 May 2025 12:45:14 By Nasdaq GlobeNewswire

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

30 Apr 2025 12:49:52 By Nasdaq GlobeNewswire

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

29 Apr 2025 10:48:02 By Nasdaq GlobeNewswire

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

29 Apr 2025 05:00:01 By Nasdaq GlobeNewswire

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

28 Apr 2025 13:36:57 By Nasdaq GlobeNewswire

Tevogen Bio Announces 2025 Annual Meeting

25 Apr 2025 11:33:05 By Nasdaq GlobeNewswire

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

17 Apr 2025 11:54:18 By Nasdaq GlobeNewswire